BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 10752474)

  • 1. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
    Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH
    Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.
    Anichini A; Mortarini R; Maccalli C; Squarcina P; Fleischhauer K; Mascheroni L; Parmiani G
    J Immunol; 1996 Jan; 156(1):208-17. PubMed ID: 8598464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
    Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
    J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
    Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
    J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
    Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
    Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.
    Skipper JC; Gulden PH; Hendrickson RC; Harthun N; Caldwell JA; Shabanowitz J; Engelhard VH; Hunt DF; Slingluff CL
    Int J Cancer; 1999 Aug; 82(5):669-77. PubMed ID: 10417764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
    Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
    J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
    Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G
    J Immunol; 1999 Feb; 162(3):1739-48. PubMed ID: 9973437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.
    Harada M; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
    Cancer Res; 2001 Feb; 61(3):1089-94. PubMed ID: 11221837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.
    Darrow TL; Slingluff CL; Seigler HF
    J Immunol; 1989 May; 142(9):3329-35. PubMed ID: 2785141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele.
    Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF
    J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.
    Kittlesen DJ; Thompson LW; Gulden PH; Skipper JC; Colella TA; Shabanowitz J; Hunt DF; Engelhard VH; Slingluff CL
    J Immunol; 1998 Mar; 160(5):2099-106. PubMed ID: 9498746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones.
    Kirkin AF; thor Straten P; Hansen MR; Barfoed A; Dzhandzhugazyan KN; Zeuthen J
    Cancer Immunol Immunother; 1999 Aug; 48(5):239-46. PubMed ID: 10478640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
    J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.